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ABSTRACT 
Calcineurin (CaN), a member of ser/thr protein phosphatase, was cloned from bovine 
retina. The peptide sequence of CaN A subunit is consisted of 511 amino acid residues. A 10 
amino acid (A-T-V-E-A-I-E-A-D-E-A) deletion before the autoinhibitory domain was 
observed in bovine retina CaN A compared to bovine brain CaN A. The study on CaN 
activity and regulation demonstrated that different metal ions have different effects on its 
phosphatase activity. Ni2+ was found to be the strongest stimulator while Zn2+ was found to 
inhibit CaN phosphatase activity. Mn2+ was a relatively less effective stimulator compared to 
Ni2+. Fe2+ was also able to stimulate CaN phosphatase activity; in contrast, a previous study 
found Fe2+ slightly inhibited bovine brain CaN activity. The residues at 97-201 were found to 
be essential for bovine retina CaN A phosphatase activity. The residues at 407-456 also had 
an inhibitory effect on CaN A phosphatase activity in addition to the previously known auto 
inhibitory domain at 457-480. These observations suggest that bovine retina CaN A might 
possess some distinct structural characteristics compared to bovine brain CaN A. 
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 1.0 REVIEW OF THE LITERATURE 
Cells, in order to maintain their growth, development, defense as well as homeostasis, 
have the ability to perceive and respond to their micro-environment. Cell signaling is a part of 
complex communication system that governs and coordinates various cellular activities. In 
addition, signal transduction refers to any process by which a cell converts one type of signal 
or stimulus into another. Most signal transduction processes involve ordered sequences of 
biochemical reactions inside the cell, which are carried out by proteins/enzymes and activated 
second messengers. Second messengers including calcium (Ca2+) and cyclic adenyl 
monophosphate (cAMP) play a major role in intracellular signal transduction. Usually, 
cytosolic Ca2+ concentration is maintained at a low level by sequestration in the smooth 
endoplasmic reticulum and mitochondria. Release of Ca2+ from endoplasmic reticulum and 
mitochondria results in the elevation of cytosolic Ca2+ level accompanied with the binding of 
Ca2+ to certain signaling proteins, which then become activated (1).   
Among all the Ca2+ binding proteins, calmodulin (CaM) is one of the most extensively 
studied proteins (2). It was discovered as a protein activator of cyclic nucleotide 
phosphodiesterase (PDE) by Cheung (3, 4). Later, Kakiuchi and Yamazaki demonstrated the 
existence of Ca2+-stimulated PDE in rat brain (5). In addition, they discovered an endogenous 
protein factor in brain that could enhance the Ca2+ sensitivity of the enzyme (5). It was 
established subsequently that the protein factor was identical to the protein activator of PDE 
later called CaM, which was originally discovered by Cheung (3, 4). The stimulation of PDE 
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required the presence of both Ca2+ and CaM (8).  
CaM is widely expressed in all cell types (6, 7). CaM is a heat-stable small acidic 
protein having a molecular mass of 17 kDa (8). It contains four “EF-hand” motifs which have 
high affinity toward Ca2+ and bind to four Ca2+ molecules (9).  Previous studies have 
suggested a mechanism of action of CaM in the activation of various enzymes (Figure 1) (3, 
10-12). CaM exhibits high affinity Ca2+-binding capacity.  In the presence of Ca2+, CaM 
undergoes a conformational change, which enables it to bind to a number of target proteins 
for specific cellular responses (13, 14), hence, it mediating multiple regulatory activities (10). 
CaM is involved in numerous biological pathways including apoptosis, Ca2+ metabolism, 
cyclic nucleotide metabolism and muscle contraction (15). In fact, CaM acts as a Ca2+ sensor 
and signal transducer (Figure 2) (16).  Calcineurin (CaN) is one of the CaM-binding proteins 
that can directly bind to Ca2+.   
1.1 Discovery of CaN 
CaN was originally discovered as a contaminant in preparation of CaM-stimulated 
cyclic nucleotide phosphodiesterase (CaMPDE) which inhibited PDE activity (11, 17-19). It 
was purified from bovine brain based on its ability to undergo a Ca2+-dependent association 
with CaM (19-22). It was designated as CaM binding protein 80 (CaMBP80) because it binds 
to CaM and has a molecular mass approximately 80 kDa (21). It contained two distinct 
subunits, CaN A and CaN B, with molecular mass of 60 kDa and 20 kDa, respectively.  
CaMBP80 was demonstrated to have inhibitory activity on CaMPDE by competing for 
binding to CaM with the latter (10, 17). Subsequently, CaMBP80 was re-named as CaN due to  
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presence of high amount in brain and intrinsic Ca2+-binding property (23). Later, Stewart et 
al. established that CaN contained CaM-dependent protein phosphatase activity (24). 
Moreover, the serine/threonine protein phosphatase family is consisted of protein 
phosphatase 1 (PP1), PP2A, PP2B (AKA PP3) and PP2C. Now, it is clear that CaN is a CaM-
dependent serine/threonine protein phosphatase 3 (PP3). Independently, studies on protein 
phosphatase-2B (PP2B) revealed that CaN and PP2B are identical proteins (24). Except 
PP2C, all other members share the same sequence homology in their catalytic domain and are 
evolutionarily related (25-27). The original classification of PP2C along side PP1, PP2A and 
CaN does not hold at the primary sequence level. PP2C is considered to be in a separate 
superfamily (28). Furthermore, all the mammalian serine/threonine protein phosphatases are 
separated into two classes (26, 27, 29, 30). Class-1 protein phosphatases were found to 
dephosphorylate the β-subunit of phosphorylase kinase while class-2 protein phosphatases 
dephosphorylate the α-subunit of phosphorylase kinase.  
1.2 CaN Properties 
CaN is a heterodimer containing CaN A and CaN B subunits (Figure 3). Mammalian 
CaN A exists in α, β, and γ isoforms while CaN B exists in B1 and B2 isoforms. The first 
suggestion that CaN has tissue-specific isoforms was supported by several independent 
studies (31). On one hand, CaN was only found to have a very high concentration in neuronal 
cells by radioimmuno-assay using an antibody raised against purified bovine brain CaN (32). 
On the other hand, CaN activity was found to be ubiquitously expressed in mammalian 
tissues (33, 34). Various investigators purified CaM-dependent phosphatases showing similar  
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structure as the bovine brain CaN from different mammalian tissues including platelet (35), 
skeletal muscle (33, 36), cardiac muscle (36), placenta (37) and pancreas (38, 39). In 
mammals, CaN A has a molecular mass range between 57-59 kDa depending on isoform. The 
size of CaN A can be approximately 20% larger in lower eukaryotes (40-46).   
Nevertheless, all CaN A genes encode for a catalytic domain homologous to other 
serine/threonine protein phosphatases and three regulatory domains that distinguish CaN 
from others. These three domains include the CaM-binding domain, CaN B-binding domain 
and auto-inhibitory domain (Figure 3). These domains have been identified through 
biochemical mapping procedures. The X-ray structures of CaN confirm the identification of 
residues involved in these regulatory domains and indicate the auto-inhibitory domain forms 
a α-helix that binds to the substratre-binding site of the catalytic domain (47). The NH2 and 
COOH termini are highly variable among species and among CaN A genes within the same 
organism (48-50). The function of the variability is unknown, but they might play a role in 
substrate-specificity and localization.   
CaN B has a molecular mass of 18 kDa and contains four EF-hand Ca2+ binding sites 
(Figure 3). The amino acids sequence of CaN B is also highly conserved among species. For 
example, mammalian CaN B is sharing 86% amino acid sequence homology with insect CaN 
B. There are two mammalian CaN B subunits. One is ubiquitously expressed along with CaN 
Aα and CaN Aβ while the other one is only found in testes along with CaN Aγ (51-53). The 
mature CaN B subunit has a myristoylation site at its NH2-terminus region (54).   
However, several studies have found that the myristoylation is required neither for 
membrane association nor for enzymatic activities (55, 56). Although the myristoylated CaN 
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B had substantial thermal stability relative to the non-myristoylated protein (56), the 
physiological role of CaN B myristoylation is unknown. Furthermore, the primary sequence 
determination of CaN B demonstrated homology with CaM and troponin C (57). EF-hand 
proteins have been classified into 39 distinct subfamilies including from two to eight EF-hand 
domains (58). Sequence alignments revealed that CaN B proteins belong to one subfamily of 
EF-hand proteins (59). CaN B has shown to be homologous to many EF-hand containing 
Ca2+-binding proteins including Ca2+- and intergrin-binding protein (CIB), a neuronal Ca2+ 
sensor (NCS-1), a protein p22/CHP (CaN homologous protein) etc. (60-62). Some studies 
have showed an overlapping function between CaN B and its homologous proteins (62-64).   
1.3 Physiological Roles of CaN 
1.3.1 In mammals 
1.3.1.1 cAMP metabolism and microtubule assembly 
In contrast to many other Ca2+-binding proteins such as troponin C, parvalbumin, and 
S-100 which have a limited distribution in certain tissues and restricted physiological 
functions; CaN is ubiquitously distributed in all tissues and possesses multifunctional 
phosphatase activity (65, 66). Several studies have proposed that CaN might play a role in 
cAMP metabolism (67). It has been demonstrated in vitro that CaN dephosphorylates 
CaMPDE, which exists in different isozymic forms (68-72). CaMPDE is involved in the 
regulation of cellular cAMP level by catalyzing the conversion from cAMP to AMP. 
Furthermore, CaMPDE can be phosphorylated; and the phosphorylation results in decrease in 
affinity towards CaM, which in turn causes a decrease in PDE activity (73, 74). However, 
CaN is able to dephosphorylate the phosphorylated CaMPDE and bring back its binding 
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affinity towards CaM accompanied with recovered PDE activity (73, 74). These findings 
fully supported that CaN is involved in cAMP metabolism.   
In addition, CaN can modulate cAMP effect by dephosphorylation (22, 75, 76).  When 
cellular cAMP level is elevated, cAMP-dependent protein kinase (cAMP-PK) will be 
activated. cAMP-PK target proteins including Inhibitor-I and DARPP-32 will be 
phosphorylated. These phosphorylated proteins have an inhibitory effect on protein 
phosphatase-1, which can dephosphorylate Inhibitor-I and DARPP-32. Thus, the cAMP 
signaling will be amplified until another phosphatase, CaN, becomes activated; hence, CaN 
will dephosphorylate Inhibitor-1 and DARPP-32. In this case, cAMP signaling will be 
terminated. And the inhibition on protein phosphatase-1will be removed.   
In addition, microtubule-associated protein-2 and tau factor are involved in 
microtubule assembly. Both proteins can be phosphorylated by either cAMP-PK or 
CaM/Ca2+-dependent protein kinase (77). The phosphorylation will inhibit the microtubule 
assembly. However, it has been found that both phosphorylated proteins can be 
dephosphorylated by CaN. The inhibition can be aborted by dephosphorylation. Thus, it is 
possible that CaN is involved in regulating microtubule assembly. 
1.3.1.2 CaN and skeletal muscle metabolism 
Moreover, CaN has been revealed to transduce Ca2+ signals from motor neurons to 
myofibers (78-80). Signals evoked by motor neurons can induce changes in metabolic gene 
expression in skeletal muscle (81). Skeletal muscle is generally divided into two types 
partially dependent on the metabolic properties: fast glycolytic and slow oxidative fibers.  
The former utilizes energy derived from glycolysis while the latter utilizes energy mainly 
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derived from lipid oxidation also known as the Krebs cycle. The impact of CaN activation on 
skeletal muscle metabolic properties including glycogenesis, glycolysis and lipid oxidation 
were studied on transgenic mice that over-express activated CaN (82). As a result, the level of 
glycogenesis was increased while the level of glycolysis was decreased comparing to wild 
type mice. In contrast, the level of lipid oxidation was increased.   
Additionally, the mRNA levels of genes encoding for proteins involved in glycogenesis 
such as hexokinase (HK2) and pyruvate dehydrogenase kinase 4 (Pdk4) were up-regulated 
while genes encoding for proteins involved in glycolysis such as aldolase (Aldoa), 
glyceraldehydes-3-phosphate dehydrogenase (Gapdh) and muscle 6-phosphofructokinase 
(Pfkm) were down-regulated. In contrast, mRNA levels of genes for lipid metabolism 
including lipoprotein lipase (Lpl), fatty acid transporter (cd36), carnitine palmitoyl-CoA 
transferase 1 (Cpt 1), mitochondrial carnitine/acylcarnitine translocase (Slc25a20), 2,4-
dienoyl-CoA reductase 1 (Decr 1) and very long chain acyl-CoA dehydrogenase (Acadvl) 
were found to be significantly elevated in MCK-can mice compared to the wild type. The 
alterations in gene expression pattern were associated with decreased glucose utilization and 
increased glycogen storage. Thus, activated CaN can regulate energy substrate utilization in 
skeletal muscle by up-/down-regulating gene expression of proteins involved in glucose or 
lipid metabolism. 
1.3.1.3 CaN and apoptosis 
CaN has been demonstrated to be involved in cell apoptosis (83) and the regulation of 
ion channels (84). Ca2+ signalling is upstream of some pathways that lead to apoptosis (85), 
for example, neuronal cell death through glutamate-induced excitotoxicity and cell death in T 
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cells (86, 87). Although many studies demonstrated the link between Ca2+ influx and cell 
death, the immediate downstream events were not revealed. Later, a Ca2+ signal mediator, 
CaN, was chosen to be a potential inducer in apoptosis (88). Apoptosis is a mechanism to 
remove cells, which experience inappropriate signals (89-91). For example, stimulation of T 
cell receptor on immature T cells drives them into apoptosis rather than proliferation (92, 93).  
In the study, CaN was demonstrated to be an inducer of Ca2+-triggered apoptosis in the 
absence of growth factor in mammalian cells (88).   
Thereafter, a mechanism of CaN -inducing apoptosis was proposed (94). L-glutamate 
triggers Ca2+ influx, which in turn activates CaN. CaN dephosphorylates a pro-apoptotic 
factor BAD, which is a member of the Bcl-2 family. The dephosphorylated BAD translocates 
from cytosol into mitochondria where heterodimerization of BAD and Bcl-X2 takes place.  
Then, apoptosis is initiated. Furthermore, the CaN -induced BAD translocation and apoptosis 
were found to be inhibited by CaN inhibitors. In addition, certain pathological states 
including prostate cancer and neuronal cell death were found to be linked to CaN -induced 
apoptosis (95-97). 
1.3.1.4 CaN and ischemia 
Myocardial ischemia is a condition in coronary artery disease. Heart tissue will be 
damaged due to lack of oxygen and other nutrients result from the blockage of artery. This 
form of heart failure is thought to be caused by loss of cardiac myocytes through apoptosis 
(98-100). CaN has been revealed as an essential regulator of cardiomyocyte apoptosis (101).  
CaN has been found to be involved in regulation of both pro- and anti-apoptotic factors (102-
104).  
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Our laboratory has investigated the alterations of CaN activity and expression in 
ischemic myocardium and demonstrated that a significant increase in CaN activity was 
observed in both animal model and patient tissue (105). However, the expression of intact 
CaN A was lower in ischemic tissue compared to normal tissue (105). Interestingly, a 
proteolysed form of CaN A, from 60 kDa to 46 kDa, was observed in ischemic tissue while it 
was not observed in normal tissue. Furthermore, the 46 kDa CaN A was found to be more 
active than that of the intact form (105). Additionally, the expression of m-calpain, a major 
Ca2+ signal mediator, was found to be increased in ischemic tissue. It was also demonstrated 
that the truncated form of CaN A was due to the controlled cleavage of CaN A by m-calpain 
in vitro (105). Thus, during myocardial ischemic condition, the elevated influx of Ca2+ causes 
activation of m-calpain, which in turn activates CaN through limited cleavage. The activated 
form of CaN will further activate pro-apoptotic factors to initiate programmed cell death in 
myocardium.   
1.3.1.5 CaN and epilepsy 
Epilepsy is a condition of seizure disorder caused by neuron damage in brain. CaN has 
attracted attention as a factor involved in this pathological condition due to its high 
expression level in brain and involvement in apoptosis pathways. Our laboratory has focused 
on the expression of CaN and its interaction with various proteins in epileptic tissue from 
animal model (106). The expression and activity of CaN were found to be increased in 
epileptic tissue compared to normal tissue (106). Moreover, the interaction between CaN and 
m-calpain was stronger in epileptic tissue than that of normal tissue (106). Since m-calpain 
can partially degrade CaN A subunit, it is highly possible that the elevated CaN activity was 
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partially contributed by m-calpain cleavage (106).  Furthermore, immunoprecipitation 
showed stronger interaction between CaN and certain apoptotic factors including Bcl-2, 
caspase-3 and p53 (106). All these data together suggest that CaN might play an important 
role in initiating apoptosis pathways in neuronal cells (107).   
1.3.1.6 CaN cleavage 
Lakshmikuttyamma et al demonstrated the proteolysis of CaN by m-calpain in vitro 
(108). A 46 kDa fragment of CaN A was observed when it was incubated with m-calpain in 
the presence of Ca2+. Two fragments, 54 and 48 kDa, were observed in the presence of CaM 
and Ca2+. No proteolysis of CaN B was observed in either condition (Figure 4) (108). CaN 
phosphatase activity was measured to see whether the activity was altered by the degradation.  
The experiment showed a 50% increase in activity upon degradation either in the presence of 
Ca2+ or Ca2+/CaM. The study also investigated whether the proteolysed fragment of CaN A 
was CaM-independent or not. The 46 kDa and 48 kDa fragments did not contain CaM-
binding site while the 54 kDa fragment did (Figure 4) (108). The study concluded that the 
proteolysis of CaN by m-calpain increased its activity and converted it into a CaM-
independent form. It is highly possible that activated m-calpain and CaN activity 
modification could contribute to the bridge between cell survival and intracellular Ca2+ 
concentration regulation.    
1.3.1.7 CaN-NFAT in skeletal muscle 
Studies based on immune system have revealed that CaN plays a crucial role in T-cell 
activation (109-115). Activated CaN dephosphorylates the nuclear factor of activated T-cells 
(NFAT), which translocates into the nucleus. NFAT will up-regulate transcription of T-cell 
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gene encoding interleukin (IL-2) and lead to T-cell activation (114, 115). The NFAT proteins 
represent a family of transcription factors widely expressed in mammalian tissues.  There are 
at least four members of NFAT including NFATc1, NFATc2, NFATc3 and NFATc4.   
Recent studies have demonstrated that the role of NFAT signaling is by no means 
restricted to the immune system. Physiological and developmental signals in cells such as 
myocytes and neurons stimulate intracellular Ca2+ transients and lead to activation of protein 
phosphatase, which in turn dephosphorylates the cytoplasmic subunit of NFAT transcription 
complexes (NFATc). In fact, NFATs are Ca2+-signaling mediators in many mammalian tissues 
including skeletal muscle, smooth muscle, cardiac muscle and pancreas. CaN-NFAT 
signaling, in coorperation with many other signaling factors, can regulate a number of 
cellular events (116-118).  
For instance, insulin-like growth factor I (IGF-I) plays a major role in muscle 
differentiation, induction of myocyte hypertrophy and regeneration of skeletal muscle (119-
121). Loss of IGF-I signaling during muscle development might result in defective growth of 
skeletal muscle (122, 123). Various studies demonstrated the cross-talk between CaN-NFAT 
and IGF-I signaling. For example, the embryonic IGF-I expression in differentiating somites 
and branchial arches is largely dependent on NFATc3 (124), which is the first NFAT protein 
to be translocated into the nucleus during skeletal myoblasts differentiation (125). The 
clustered NFAT consensus binding sequences were found in two highly conserved regions 
that identified in the 5’-flanking regions of the IGF-I exon 1 promoter (126).   
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Figure 4 
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In addition to these NFAT binding sites, some known myogenesis regulators such as 
CEBP, E-box and MEF2 binding sites were also found near the IGF-I exon1 promoter region.  
This implies a possible pathway to regulate IGF-I gene expression during muscle 
development. Indeed, these NFAT binding sequences were found to be responsive to CaN-
NFATc3 signaling; and IGF-I gene expression was induced by NFATc3 in the presence of 
activated CaN. Thus, the identification of CaN-NFAT responsive sequence in the IGF-I gene 
implies a possible mechanism to regulate muscle development and homeostasis by the two 
pathways.   
For instance, IGF-I and CaN-NFAT signalling were revealed to be responsible for 
skeletal muscle hypertrophy (127-129). The hypertrophic response was observed in both 
transgenic mice treated with IGF-I and transgenic mice expressing constitutively activated 
CaN (127). Essentially, IGF-I can activate CaN by increasing intracellular Ca2+ 
concentration.  Once CaN is activated, NFAT is dephosphorylated and translocated into 
nucleus, where the expression of GATA-2, a skeletal muscle hypertrophy marker, is induced. 
GATA-2 will further activate gene expression programs toward development of hypertrophic 
responses.  On the other hand, the hypertrophy was repressed in transgenic mice expressing a 
dominant-negative form of CaN or by addition of CaN inhibitors. 
1.3.1.8 CaN signaling in smooth muscle 
Vascular smooth muscle cells (VSMCs) can undergo phenotypic modulation and act as 
a major component of thickened arterial intima (130). Changes in the expression pattern of 
smooth muscle-myosin heavy chain (Sm-MHC) are accompanied with the development of 
phenotypic modulation (131-134). The Sm-MHC gene is a downstream target of GATA-6 
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which plays a role in the VSMC differentiation (135). GATA-6 is a zinc-finger protein 
belongs to a family of transcription regulators.   
It has been revealed the connection between CaN-NFAT and GATA-6 during smooth 
muscle differentiation (130). First of all, Sm-MHC promoter was not activated when GATA-6 
could not bind to the gene. CaN was also required for the transcription activation of Sm-
MHC gene because the the promoter activity was largely reduced when VSMCs were treated 
with CaN inhibitors during differentiation (130).  Moreover, the binding of GATA-6 to Sm-
MHC gene was significantly inhibited in the presence of CaN inhibitors.  In other words, 
CaN is required for GATA-6 binding to the DNA. The study also showed the interaction 
between GATA-6 and NFATc1 which is the major isoform of NFAT found in smooth muscle, 
through the zinc-finger domain of GATA-6. In addition, Sm-MHC gene expression level was 
reduced with the treatment if CaN inhibitors in differentiated VSMCs (130). Thus, CaN-
NFAT, in coorperation with GATA-6, are involved in regulation Sm-MHC gene expression. 
These three proteins together build up a possible signaling pathway for the maintenance of 
differentiated phenotype in VSMCs. This finding may lead to designing therapeutic agents 
against diseases involving vascular injury. 
1.3.1.9 CaN-NFAT and cardiac hypertrophy 
Cardiac hypertrophy is a major risk factor for the development of heart failure. In 
response to various pathologic stimuli, the myocardium undergoes growth in length and/or 
width in order to increase cardiac pump function and decrease ventricular wall tension (136, 
137).  The initial stimuli can be divided into two categories: biomechanical and stretch-
sensitive mechanisms, and neurohumoral mechanisms (138). A number of ligands such as 
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angiotensin II, catecholamines, neuregulin and IGF-I etc. are sensed by cardiac myocytes 
through various membrane-bound G-protein-coupled receptors (GPCRs) (138). These 
receptors will initiate a number of intracellular signaling pathways to mediate cardiac growth 
response (138).  Alterations of gene expression in the nucleus and concentrations of proteins 
in the cytoplasm will be involved in such signaling pathways to coordinate hypertrophic 
response (138).   
CaN was identified to play a central role in hypertrophic responses (139), such as 
ligands/G-protein-coupled receptors (GPCRs) induced and biomechanically induced cardiac 
hypertrophy (138). Several studies have provided evidences to demonstrate the importance of 
G-protein-coupled receptors in pathological cardiac hypertrophy (140-143).  For example, 
overexpression of Gαq/α11, a G protein, increased the tendency of cardiac hypertrophy under 
pressure-overload condition and resulted in heart failure (140-143).  However, inhibition of 
Gαq/α11 resulted in the decrease of such hypertrophic response under pressure-overload 
condition (144, 145). In addition, Gαq/α11 induced hypertrophy is not required for normal heart 
functional compensation (138). Furthermore, CaN-NFAT signaling was proposed to be part of 
the downstream events of GPCR-induced hypertrophy (138). G proteins of Gαq/α11 are 
activated through binding of ligands such as Ang II, Endo-1 and catecholamines. Activated G 
proteins are coupled to phospholipase Cβ (PLCβ). This coupling will induce the generation of 
diacylglycerol (DAG), which will activate protein kinase C (PKC). Activation of PKC will 
lead to production of inositol-1,4,5-triphosphate (Ins(1,4,5)P3) (146). Accumulation of 
Ins(1,4,5)P3 results in release of Ca2+ from endoplasmic reticulum or the nuclear envelope. 
Increase of intracellular Ca2+ concentration will lead to activation of various proteins such as 
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CaM, CaMPK and CaN. These proteins will further activate prohypertrophic gene expression 
by dephosphorylating and translocating NFAT (147, 148).   
Addition to GPCR initiated mechanism, biomechanically induced hypertrophy also 
involves CaN-NFAT signalling pathway (149, 150). There are two sensing apparatus that 
have been proposed to transduce biomechanical stress signals through attached signalling 
molecules (138). One is consisted of three components including extracellular matrix, 
integrins, which are heterodimeric transmembrane receptors, and intracellular cytoskeleton 
(151). The other sensing apparatus is thought to be located at the level of Z-disc within each 
sacomere (152). The small LIM-domain protein, muscle LIM protein (MLP), is anchored to 
specific proteins at the Z-disc. It has been proposed to act as an internal stretch sensor 
through a complex of transducing proteins including CaN-NFAT signalling pathway (149, 
150, 152).   
In both mechanisms, activation of CaN and translocation of NFAT into the nucleus are 
proposed to be the crucial events which lead to cardiac hypertrophy. For example, inhibition 
of CaN resulted in reduced hypertrophy response upon pressure-overload condition (153). 
Transgenic mice with disrupted expression of NFATc3 were demonstrated to have reduced 
myocardial growth in response to activated CaN gene or in pressure-overload condition or 
other extracellular signals (147). Additionally, cardiac hypertrophy induced by CaN-NFAT 
signalling can be negatively regulated by kinases such as p38 and c-Jun N-terminal kinases 
(JNKs), which are activated through mitogen-activated protein kinase (MAPK) (154-156). 
These kinases are proposed to antagonistically attenuate the dephosphorylation of NFAT by 
CaN.   
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1.3.1.10 CaN and glaucoma   
Glaucoma is one of the leading causes of irreversible blindness in the United States 
(157). The principle factor for developing glaucoma is the elevated intraocular pressure 
(IOP), which further leads to retinal ganglion cell (RGC) death (158, 159). The RGC death is 
driven by apoptosis pathways (160-163). However, the upstream mechanisms initiating the 
apoptosis were not known (164). The primary treatment is to lower the IOP; however, many 
patients still lose vision despite aggressive treatment (160). In order to improve the efficiency 
of treatment, the mechanism of how elevated IOP resulted in RGC death needed to be 
investigated.   
CaN has been found to be a critical regulator of Ca2+-induced apoptosis pathways (164).  
It was revealed to dephosphorylate the proapoptotic Bcl-2 family member, BAD (165). The 
dephosphorylated BAD further leads to cytochrome c (cyt c) release, caspase activation, and 
apoptotic cell death (165, 166). Recently, one research group has demonstrated a possible 
pathway, which mediates the effect of increased IOP to RGC death (164). The major finding 
from this study is the correlation between elevated IOP and cleavage of CaN A. Western blot 
analysis was done by using antibody specific for full length (60 kDa) CaN A and truncated 
(46 kDa) CaN A (167, 168). The truncated CaN A was observed in half of the eyes with 
elevated IOP for 5 days and in all eyes with elevated IOP for 10 days. The observation from 
an experiment based on the DBA/2J mouse model of spontaneous glaucoma further 
confirmed the result. In addition, experiments were performed to verify the limited cleavage 
of CaN A was a specific apoptosis event.   
According to Berkelaar et al., RGC loss took place in the eyes of rats that underwent 
optic nerve (ON) crush after 8 days (169). Huang et al. performed immunoblot analysis on rat 
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eyes that underwent ON crush at three time points; and no truncated CaN A was observed. In 
order to prove that CaN’s contribution to RGC death and ON damage, Huang et al. compared 
the level of RGC death and ON damage between experimental glaucoma and experimental 
glaucoma with CaN inhibitor administrated (164). The immunosuppressant drug FK506 was 
used to inhibit CaN’s activity (170). RGC loss after 10 days of elevated IOP was estimated as 
33.6 ± 2% of RGC.  After oral treatment with FK506, there was only a 16.7 ± 3% loss of 
RGC.  In a pilot experiment, they assessed the degree of ON damage after 10 days of 
elevated IOP with/without FK506 treatment (164). A significant ON preservation was 
observed with FK506 treatment.   
Furthermore, they examined the mechanism which led to BAD dephosphorylation and 
mitochondria release of Cyt c; and by which mechanism CaN inhibition resulted in the 
preservation of RGC. Phosphorylated BAD (pBAD) is inactive, while dephosphorylated Bad 
is active and targeted to mitochondria, where it cause cell death (166). Huang et al. assessed 
the level of pBAD in retinal cell cytoplasm from eyes with/without elevated IOP using a 
pBAD-specific antibody. The level of pBAD is significantly reduced in eyes with high IOP. 
Treatment with FK506 significantly increased the level of pBAD in eyes with high IOP. They 
went further to measure the levels of Cyt c in the cytoplasm and the mitochondria in eyes 
with high IOP. In eyes with high IOP, level of Cyt c was increased in the cytoplasm and 
decreased in the mitochondria; also, FK506 was able to inhibit the translocation of Cyt c from 
mitochondria to cytoplasm. 
As a result, in the experimental glaucoma, CaN is cleaved into a constitutively active 
form; the CaN activation further enhanced pBad dephosphorylation and Cyt c release which 
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both contribute to the apoptotic RGC death. This study has revealed the molecular events that 
correlated to RGC death in experimental glaucoma. It will contribute to the future 
investigation of the biochemical mechanisms of glaucoma in patients. 
1.3.2 In lower eukaryotes 
A number of studies have revealed that CaN plays various roles in lower eukaryotic 
organisms (171, 172). For instance, CaN is involved in cell cycle progression through G1/S1 
nuclear division, polarized growth and proper septation in Aspergillus nidulans (173, 174). It 
is also playing a role in differentiation and stalk cell/spore formation in Dictyostelium 
discoideum (175). In addition, CaN has been linked to virulence, pH and CO2 homeostasis, 
temperature-sensitive growth and resistance to Li+ in Cryptococcus neoformans (176).   
1.3.3 In plants 
The first evidence that demonstrated a plant homolog of CaN was provided by using 
immunosuppressant drugs cyclosporine (CsA) and Tacrolimus (FK506) (177). For instance, 
CsA and FK506 blocked Ca2+-dependent inactivation of K+ channels in Vicia faba while a 
constitutively active form of CaN inhibited K+ channel activity. To date, there is no CaN 
purified from plant tissue. There is no gene that has been cloned for CaN from plant either. 
The proteins that are closely related to CaN are two EF-hand Ca2+-binding proteins: SOS3 
proteins and AtCBL proteins (178, 179). Studies on these proteins indicate that salt stress in 
plants might be regulated by Ca2+-dependent signaling pathways (63). 
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1.4 CaN in Eye Tissues 
The roles of CaN in other organs have implicated its potential functions in eye tissues.  
Our laboratory has reported that CaN is present in all eye tissues, although the activity and 
protein expression (including CaN Aα and CaN Aβ isoforms) varied (180). The highest levels 
of CaN phosphatase activity and protein expression were observed in retina, optic nerve and 
cornea (180). The implications from this study expanded the insights of CaN’s potential roles 
in eye tissues.   
The presence of both isoforms of CaN A suggests a possibility that CaN might be 
involved in immunoregulation since CaN Aβ is predominantly expressed in lymphoid cells 
and is responsible for mediation of the immune response (181). Regarding to corneal 
transplantation, expression of CaN and FasL in cornea will be an important factor in 
determining survival of grafts since CaN is found to be necessary for the expression of FasL 
(164).  
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2.0 RATIONALE  
CaN is observed in chick retina (183), in the developing and mature mammalian 
retina (184) and bovine eye tissues (180). In addition to the potential pathway for regulation 
by CaN in cornea, the response of retinal photoreceptor cells to light is another potential 
pathway for regulation by CaN. During the photoreceptor cycle a series of reactions result in 
a net decrease of cGMP concentrations in photoreceptors, causing an inactivation of cGMP-
gated cation channels that allows the photoreceptor to extrude ions and return to a resting 
potential (185). One of the ions regulated in this process is Ca2+. Intracellular Ca2+ 
concentrations in photoreceptors are also mediated by release from intracellular stores by the 
interaction of inositol triphosphate (IP3) (186, 187) with its receptor.  
Ca2+ concentrations in photoreceptors could also be regulated by CaN. The pathways 
involving CaN could suppress the amplitude of Ca2+ oscillations in photoreceptors facilitating 
a more rapid transition from the light- to the dark-adapted photoreceptor (Figure 5). Such a 
possible pathway could account for the relatively high amounts of CaN demonstrated in the 
retina. 
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Figure 5 
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 3.0 SPECIFIC OBJECTIVE 
z To clone bovine eye retina CaN A and B subunits.  
z The biochemical characterization of recombinant CaN A subunit. 
z To analyze the domain organization of recombinant CaN A subunit. 
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4.0 MATERIALS AND METHODS 
4.1 Materials 
Bovine eyes were obtained from a local slaughter house. They were transferred to the 
laboratory on ice and stored at -70 oC until use. The expression vector pQE9 was purchased 
from Qiagen, Canada. Restriction endonucleases and DNA modifying enzymes were 
purchased from Invitrogen, Canada. Ligation Pack was purchased from New England 
Biolabs, USA. Nitrocellulose sheets were purchased from Bio-Rad Laboratories, Canada. 
Protein markers were purchased from Invitrogen, Canada. General analytical grade laboratory 
chemicals were purchased from various commercial sources as listed in table 1. 
4.1.1 Bacterial strains and growth media 
For cloning purpose, QIAGEN EZ competent cells were purchased from QIAGEN, 
Canada. The genotype of QIAGEN EZ competent cells is [F’::Tn10(Tc’) proA+B+ 
laclqZ∆M15] recA1 end A1 hsdR17 (rk12-mk12+) lacglnV44 thi-1 gyrA96 relA1. For 
expression of CaN, bacterial strain, Escherichia coli M15[pREP4], was used (QIAGEN, 
Canada). The cells were grown in Luria Broth (LB) containing 1.0% (w/v) bacto-tryptone, 
0.5% (w/v) bacto-yeast extract and 1.0% (w/v) NaCl, pH 7.0, per liter. The LB dehydrated 
ingredients were dissolved in deionized water and autoclaved for 20 min. at 120 oC. Filter 
sterilized ampicillin was also added to autoclaved LB in a final concentration of 100 µg/mL. 
4.1.2 Plasmids and vectors 
For cloning of CaN, pDrive cloning vector was used (QIAGEN, Canada). It contains the 
following elements: Mulltiple cloning site, LacZ α-peptide, T7 RNA polymerase promoter, 
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T7 transcription start, SP6 RNA polymerase promoter, SP6 transcription start, ampicillin 
resistant gene, kanamycin resistant gene, pUC origin, phage f1 origin, primer binding sites, 
M13 forward, M15 forward, M13 reverse, T7 promoter primer, and SP6 promoter primer 
sites. 
For overexpression of CaN, pQE9 expression vector was used (QIAGEN, Canada). It 
provides high level expression of 6xHis-tagged proteins in E.coli. pQE plasmids were derived 
from plasmids pDS56/RBSII and pDS781/RBSII-DHFRS. It contains the following 
elements: multiple cloning site, T5 promoter, lac operator, ribosome binding site, His-tag 
sequence, stop codons, Col E1 origin of replication, and ampicillin resistant gene. 
4.2 Methods 
All methods were conformed to the Guide for the Care and Use of Laboratory Animals 
described and approved by the University of Saskatchewan, Saskatchewan, Canada.   
4.2.1 Production of CaN antibody 
A polyclonal antibody against CaN was raised in New Zealand white rabbits as 
described previously (180). Briefly, multiple subcutaneous injections of 50 µg bovine brain 
CaN emulsified with complete Freund’s adjuvant (CFA) were given at multiple sites. The 
first blood samples were obtained on day 36, and two boosters were given with the same 
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Table 1. Chemicals and reagents used during current study. 
Reagents and chemicals Company, Country Catalog number 
Tris base Invitrogen, Canada 15504-020 
NaCl Sigma-Aldrich, USA 7647-14-5 
Imidazole BDH laboratory supplies, Canada EM-IX0005-2
IPTG Invitrogen, Canada 15529-019 
pNPP Sigma-Aldrich, USA 698999-89-2 
2-mercaptoethanol Sigma-Aldrich, USA 60-24-2 
Western lightning 
chemiluminescence reagent 
plus 
PerkinElmer LAS, Inc., USA NEL104 
Bio-Rad Protein Assay Bio-Rad, USA 500-0006 
EGTA Sigma-Aldrich, USA 67-42-5 
SDS BDH chemicals, Canada EM-7910 
X-GAL Invitrogen, Canada 15520-018 
Ampicillin sodium salt Invitrogen, Canada 11593-019 
Goat Anti-Rabbit 
IgG(H+L)-HRP conjugate Bio-Rad, USA 170-6515 
Lysozyme Sigma-Aldrich, USA 12650-88-3 
BenchMark protein ladder Invitrogen, Canada 10747-012 
BenchMark pre-stained 
protein ladder Invitrogen, Canada 10748-010 
1 kb DNA Ladder Invitrogen, Canada 15615-016 
[γ-32P]ATP PerkinElmer LAS, Inc., USA BLU002 
BamHI Invitrogen, Canada 15201-023 
HindIII Invitrogen, Canada 15207-020 
Acrylamide Invitrogen, Canada 15512-023 
Agarose Invitrogen, Canada 15510-027 
Nitrocellulose Membrane Bio-Rad, USA 162-0115 
X-Omat Blue XB-1 Kodak, USA 1776699 
Blotting Grade Blocker 
Non-Fat Dry Milk Bio-Rad, USA 170-6404 
Bovine Serum Albumin Sigma-Aldrich, USA 9048-46-8 
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amount of antigen in CFA, one on day 37 and the other on day 56. Subsequent blood samples 
were obtained on days 55 and 60. The sera were separated from the blood samples and stored 
at -20 oC until use. The antibody titer was determined by using ELISA (188). The 
immunoglobulins were purified through a protein A-Sepharose-4B column, which was pre-
equilibrated with 100 mM Tris-HCl, pH 8.0, followed by elution of bound IgG with 100 mM 
glycine, pH 2.5.  The pH was adjusted to 8.0 with 1 M Tris immediately after elution. The 
immunoglobulin was dialyzed against phosphate-buffer saline (PBS) overnight. The antibody 
was demonstrated to be specific for CaN. The dialyzed sample was stored at -70 oC until use. 
4.2.2 Preparation of CaM 
Bovine brain CaM was purified by using a phenyl-Sepharose column as described by 
Gopalakrishna and Anderson (189). It was further purified by using a Sephacryl S-200 gel 
filteration column which was pre-equilibrated with Buffer A (20 mM Tris-HCl, 1 mM 
magnesium acetate, 1 mM imidazole, pH 7.0, 10 mM 2-mercaptoethanol) containing 0.01 
mM Ca2+ and 0.1 M NaCl.   
4.2.3 Preparation of cAMP-PK 
Bovine heart cAMP-PK was purified to homogeneity as described by Demaille et al. 
(190). Bovine heart was homogenized in 2.5 vols of 4 mM EDTA, 0.2 mM mercaptoethanol, 
pH 7.0 and centrifugated at 7,000 X g for 30 minutes. The supernatant was filtered through 
glass wool and pH was adjusted to 7.6.  The clear supernatant was added to DEAE-Sepharose 
6B Cl which was pre-equilibrated with buffer A (50 mM Tric-HCl, pH 7.6, 10 mM NaCl, 4 
mM EDTA, 0.2 mM mercaptoethanol) and mixed overnight. Filtered the suspension on 
sintered glass funnel and washed the DEAE-Sepharose 6B Cl thoroughly with buffer A. 
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DEAE-Sepharose 6B Cl column was prepared and equilibrated with buffer A. The washed 
from sintered galss funnel was loaded to DEAE-Sepharose 6B Cl column and eluted with 
buffer A containing 0.5 M NaCl. (NH4)2SO4 was added to the eluent in a final concentration 
of 176 g/L and mixed for 1 hour. The suspension was centrifuge at 11,000 X g for 45 minutes. 
(NH4)2SO4 (314 g/L) was added to the supernatant and adjusted pH to 7.0 and mixed for 1 
hour. Then, centrifuge at 11,000 X g for 45 minutes and redissolved the pellet in minimum 
volume of buffer B (30 mM K2HPO4, pH 7.0, 1 mM EDTA, 0.2 mM mercaptoethanol) and 
dialyzed overnight against buffer B. Then, the dialysed supernatant was adjusted pH 6.1. 
Then, resulted supernatant was mixed with CM Sephadex C-50 which was pre-equilibrated 
with buffer C (30 mM K2HPO4, pH 6.1, 1 mM EDTA, 0.2 mM mercaptoethanol). cAMP was 
added to filtrate to a final concentration of 10 µM and incubated for 1 hour with 60 mL CM 
Sephadex C-50 pre-equilibrated with buffer C. Then, filtered on a Buchnner funnel and 
washed with 12 volume of buffer C. The resin was resuspended in a minimum volume of 
buffer C and packed in a column and washed with 50 mL of buffer C. Proteins was eluted 
with buffer C containing 1.0 M KCl and collected ~5.0 mL fraction at 25 mL/hour. Pooled 
A280 absorbing fractions and concentrated to minimum volume. Centrifuged at 30,000 rpm 
using 75 Ti rotor for 30 minutes. Supernatant was loaded on a column of Sephacryl S-200 
which was equilibrated with buffer D (30 mM K2HPO4, pH 7.0, 1 mM EDTA, 2 mM 
mercaptoethanol and 0.15 M KCl). The fractions were collected and analyzed for cAMP-PK 
activity. The highest enzyme activity fractions were pooled and stored at -80 oC for further 
analysis.   
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4.2.4 Molecular cloning of bovine retina CaN A and CaN B 
General cloning techniques were carried out essentially as described by Sambrook et 
al. (191). Total RNA was prepared from bovine retina muscle using the RNeasy mini kit 
(Qiagen). Reverse transcription-polymerase chain reactions (RT-PCR) were carried out using 
sense and antisense oligonucleotide primers specific for CaN A and B. Primers were designed 
based on the bovine brain CaN A (accession number U33868) and CaN B (accession number 
NM174583) sequences. The retina CaN A and B cDNAs were amplified by employing PCR 
using GeneAmp PCR System 9600 (Perkin–Elmer, USA) using two primers with restriction 
sites (underlined) for BamHI and HindIII using one-step RT-PCR (Qiagen, Canada) (Table 2). 
The details of primer sequences were shown in the table 3. The amplified PCR product was 
purified from agarose gels using a QIAquick gel extraction kit (Qiagen, Canada). Resulting 
DNA fragments (CaN A and CaN B) were cloned into the pCR-Zero Blunt vector using the 
pCR-TOPO cloning kit (Invitrogen, Canada). The recombinant plasmid (BT-CaN-A- Zero 
Blunt) was subjected to DNA sequencing to check the nucleotide sequences of the amplified 
genes. The complete nucleotide sequence was determined by the dideoxy chain termination 
method using a DNA sequencer (Applied Biosystem Model 310A). The CaN A gene was 
excised with BamHI and HindIII and ligated into the expression vector pQE9 (previously 
digested with same restriction enzymes), resulting in plasmid BT-CaN A-pQE9. Similarly, 
CaN B was cloned as described above using CaN B specific primers. 
4.2.5 Expression and Purification of recombinant retinal CaN A and CaN B 
For the expression of recombinant protein, BT-CaN-A-pQE9 was transformed into E. 
coli M15 (pREP4) competent cells and grown in LB medium (100 µg/ml ampicillin) at 37 °C 
with shaking. After reaching an optical density of 0.4–0.6 at 600 nm the production of target 
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protein was induced by the addition of isopropyl-beta-D-thiogalactopyranoside (IPTG) (to 
1 mM). Cells were induced for 5 hour and were harvested by centrifugation (8000 X g, 
20 minutes at 4 °C). Cells were suspended in lysis buffer (50 mM Tris–HCl, pH 8.0, 300 mM 
NaCl, 10 mM imidazole) and were lyzed by addition of lysozyme to a final concentration of 
1 mg/ml on ice for 30 minutes. This was followed by sonication in a Sonics VibraCell 
Sonicator, for 12 X 15 s bursts. The lysate was cleared by centrifugation (14,000 X g, 
30 minutes at 4 °C) and loaded on to a Ni-NTA agarose column, equilibrated with lysis 
buffer. The column was washed until no protein with wash buffer (50 mM Tris–HCl, pH 8.0, 
300 mM NaCl and 20 mM imidazole), and the bound protein was eluted from the column 
using elution buffer (50 mM Tris–HCl, pH 8.0, 300 mM NaCl and 250 mM imidazole). 
Similarly, the CaN B was expressed and purified as described above.  
4.2.6 CaN assay 
CaN activity was assayed using pNPP as a substrate (192). The reaction mixture 
consists of 50 mM Tris–HCl, pH 7.0, 5 µg CaM, 3.4 mM pNPP, 15 µg CaN A and 10 µg CaN 
B in total volume of 1.0 ml. Ca2+-independent activity of CaN was determined under identical 
conditions in the presence of 5 mM EGTA. The reaction was incubated at 30 °C for 30 
minutes. The reaction was initiated by the addition of pNPP and terminated by the addition of 
75 mM K2HPO4. The pNPP hydrolysis was quantified by the increase of absorbance at 405 
nm. One unit of phosphatase activity was defined as the amount of dephosphorylation  
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 Table 2. PCR conditions of CaN Subunits 
 
cDNA of CaN subunits RT-PCR conditions 
CaN A 
50 °C for 30 minutes, 
95 °C for 15 minutes, 
35 cycles of (94 °C for 15 seconds,  
53 °C for 30 seconds, 72 °C for 2 minutes), 
72 °C for 10 minutes. 
    CaN B 
50 °C for 30 minutes, 
95 °C for 15 minutes, 
35 cycles of (94 °C for 15 seconds,  
51 °C for 30 seconds, 72 °C for 30 seconds), 
72 °C for 10 minutes. 
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 Table 3. Primers for RT-PCR of WT CaN and Various Mutants. 
 
CaN subunit RT-PCR primers 
CaN A 
Forward: 5’-GGATCCATGTCCGAGCCCAAGGCAAT-3’ 
Reverse:5’-AAGCTTTCACTGGATATTGCTGCTATTACTGCC-3’ 
∆1  
CaN A97-511 
Forward:5’-GGATCCGACTTGATGAAACTCTTTGAAGTGGGG-3’
Reverse: 5’-AAGCTTTCACTGGATATTGCTGCTATTACTGCC-3’ 
∆2  
CaNA201-511 
Forward: 5’-GGATCCGGCGGTTTGTCTCCAGAGATAAACA-3’ 
Reverse: 5’-AAGCTTTCACTGGATATTGCTGCTATTACTGCC-3’ 
∆3  
CaN A1-456 
Forward: 5’-GGATCCATGTCCGAGCCCAAGGCAAT-3’ 
Reverse: 5’-AAGCTTCCCAACAAACGGCAGGGAC-3’ 
∆4  
CaN A1-406 
Forward: 5’-GGATCCATGTCCGAGCCCAAGGCAAT-3’ 
Reverse: 5’-AAGCTTCATCTTGCCAATGGCTCGGA-3’ 
∆5  
CaN A1-358 
Forward: 5’-GGATCCATGTCCGAGCCCAAGGCAAT-3’ 
Reverse: 5’-AAGCTTTAAGCCCTTGGCCTCCTCGA-3’ 
CaN B 
Forward: 5’-GGATCCATGGGAAATGAGGCAAGTTATCCTTTG-3’ 
Reverse: 5’-AAGCTTTCACACGTCTACCACCATCTTTTTGTG-3’ 
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resulting in an optical density of 0.1 at 30 °C after 30 minutes incubation.  
4.2.7 Effects of metal ions on CaN activity 
To determine the effect of metal ions on CaN phosphatase activity, the recombinant 
retinal CaN incubated with 1 mM Ni2+, Fe2+, Mn2+or Zn2+ in the reaction mixture as 
described in 4.2.6. 
4.2.8 Deletion analysis 
All deletion constructs were generated by PCR using specific oligonucleotide primers 
(Table 3) and standard methodologies as detailed previously. All constructs generated by PCR 
were sequenced to eliminate potential mutations incorporated during the PCR. All mutants 
were expressed and purified as described above. 
4.2.9 Phosphorylation and dephosphorylation of histone 
Histones were phosphorylated essentially as previously described by Sharma (193). 
The standard reaction mixture consists of 100 mM Tris–HCl, pH 7.0, 5 mM MgCl2, 5 mM 2-
mercaptoethanol, histone (2 mg/mL), 0.1 mM [γ-32P]ATP (150–200 cpm/pmol) and catalytic 
subunit of cAMP-PK (20 µg/mL) in the presence of 0.1 mM EGTA. After incubation for 60 
minutes an aliquot was taken for the determination of phosphate incorporation. The 
remaining sample of phosphorylated histone will be dialyzed overnight with several changes 
against 20 mM Tris–HCl, pH 7.0 and 10% sucrose to remove the unreacted [γ-32P]ATP. For 
dephosphorylation of histone, the phosphorylated histone (0.2 mg/mL) was incubated at 30 
°C in a reaction mixture containing 100 mM Tris–HCl, pH 7.0, 5 mM 2-mercaptoethanol, and 
CaM (100 µg/mL) with the addition of retina WT CaN A (15 µg/ml) or various truncated 
mutants (15 µg/mL) and retina CaN B (10 µg/mL) incubated with 0.1 mM Ni2+. The retinal 
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CaN A or various truncated mutants and CaN B were incubated with 1 mM Ni2+ at room 
temperature for 1 hour prior to the incubation of phosphatase reaction. 
4.2.10 SDS-PAGE and Western blot analysis 
Purified retinal recombinant CaN A and B were separated on 10% and 15% SDS-
PAGE, respectively, according to the procedure described by Laemmli (194). The bacterially 
expressed retina CaN A and B were transferred to nitrocellulose using the immunoblot 
method of Towbin et al (195). The blot was incubated first with the CaN specific polyclonal 
antibody at a dilution of 1:1000, washed and probed with an anti-rabbit IgG horseradish 
peroxidase conjugate (Bio-Rad) diluted 1:2000. Membranes were incubated in 
chemiluminescence reagent (NEN Life Science Products, USA) and exposed to Kodak X-
OMAT Blue XB-1 film for the detection of CaN. 
4.2.11 Other methods 
Protein concentrations were measured by the method of Bradford (196) using bovine 
serum albumin as a standard. The nucleotide and amino acid sequences were evaluated using 
the MacVector (version 7) computer program. 
4.2.12 Statistical analysis 
All data were analyzed as the mean ± S.E. The difference between the mean values 
was tested by the two-tailed Student's t-test for statistical significance. 
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5.0 RESULTS AND DISCUSSIONS 
5.1 Cloning of CaN A and CaN B 
In order to characterize the biochemical and structural properties of bovine retina 
CaN, molecular cloning techniques were employed. Total RNA was isolated from bovine 
retina cells.  Two pairs of DNA primers were designed based on bovine brain CaN A and CaN 
B subunits.  Then, the cDNA copies of CaN A and CaN B were obtained by using a one-step 
RT-PCR kit.  The retinal CaN A cDNA and CaN B cDNAs were subjected to 1% and 2% 
agarose gel electrophoresis, respectively, to visualize the size and purity of the PCR products 
(Figure 6). A single band was observed for each subunit: CaN A and CaN B, 1500 bp and 500 
bp, respectively (Figure 6).   
The cDNA copies of the two subunits were purified from agarose gel using a 
QIAquick gel extraction kit. Resulting DNA fragments were cloned into the pCR-Zero Blunt 
vector using pCR-TOPO cloning kit. The recombinant plasmid BT-CaN A-Zero Blunt was 
subjected to DNA sequencing to confirm the nucleotide sequence of retinal CaN A (Figure 7). 
The complete sequence of CaN A specifies 1536 nucleotides. It was translated into peptide 
sequence and subjected to comparison with CaN A peptide sequences from other sources or 
species (Figure 8).   
Bovine eye CaN A has 10 amino acids deletion: A-T-V-E-A-I-E-A-D-E-A, between 
447 and 458 compared to bovine brain CaN A. There was also one amino acid difference at 
position 367 (aspartic acid → asparagine) between bovine eye CaN A and bovine brain CaN 
A (Figure 8). However, it was found that bovine eye CaN A was sharing 100% identity with  
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 bovine heart CaN A. Despite the 10 amino acids deletion, there were three amino acid  
substitutions: threonine → serine at position 59, aspartic acid → asparagine at position 367, 
alanine → threonine at position 504, between bovine eye CaN A and human CaN A (Figure 
8). There were three amino acid substitutions: threonine → serine at position 59, glutamic 
acid → aspartic acid at position 267, aspartic acid → asparagine at position 367, between 
bovine eye CaN A and rat CaN A, addition to the 10 amino acids deletion (Figure 8). Rat 
brain and mouse brain CaN A share 100% sequence identity. The results suggest that CaN A 
sequence is highly conserved in mammals. It is highly possible that the functionality and 
physiological roles of CaN A among these species are more or less the same. CaN A might 
play important roles in biological systems since it is widely expressed in various species and 
tissues. 
5.2 Expression and purification of CaN A and CaN B 
CaN A DNA was excised by using endonuclease digestion with BamHI and HindIII.  The 
gene was then ligated into an expression vector pQE9, resulting in plasmid BT-CaN A-pQE9. 
CaN B was cloned into pQE9 in the same procedure. To express both subunits, the resulting 
plasmids were transformed into E. coli M13 (pREP4) separately. The expressions of both 
proteins were induced by using IPTG as described in section of Materials and Methods.  The 
recombinant retinal CaN A was linked to a 6X Histidine tail at its NH2-terminus. The 
purification of the recombinant protein was carried out by applying crude lysate to Ni-NTA 
agarose column. The His-tagged protein was tightly bound with the Ni-coated column while 
other proteins and impurities were flow through and rinsed out from the column. Thereby, 
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this single step purification was efficient enough to obtain the purified CaN A.  Retinal CaN 
B recombinant protein was also purified in the same procedure.   
In order to judge the purity and estimate the sizes of CaN A and CaN B, both proteins 
were subjected to 10% and 15% SDS-PAGE, respectively (Figure 9). CaN A was migrated 
with a molecular mass of approximately 60 kDa while CaN B was migrated with a molecular 
mass close to 20 kDa. In order to confirm the identity of visualized bands on SDS-PAGE, the 
bands were transferred onto a nitrocellulose membrane and incubated with polyclonal 
antibody raised against bovine brain CaN (Figure 10). Both CaN A and CaN B protein bands 
were detected by the antibody at the correct position relative to the pre-stained protein 
marker.  Thus, both proteins were purified successfully to near homogeneity. 
5.3 CaN phosphatase activity and effect of metal ions 
Once both subunits were purified, the enzymatic activity of CaN was examined.  CaN 
A has the phosphatase activity since it contains the active site. However, the association of 
CaN A and CaN B subunits is required to achieve its full activity. In order to study the 
stoichiometry ratio between the two subunits, the reconstitution assay was carried out with a 
constant concentration of CaN A and various concentrations of CaN B subunits (Figure 11). 
As a result, the CaN phosphatase activity reached maximal level when stoichiometry ratio 
between CaN A and CaN B was 1:2. The maximal CaN A phosphatase activity was reached 
when one molecule of CaN A subunit binds to two molecules of CaN B subunits. Therefore, 
all the subsequent phosphatase activity assays were carried out at this molar ratio. 
Furthermore, the effects of metal ions including nickel (Ni2+), ferric (Fe2+), mangness (Mn2+) 
and zinc (Zn2+) on CaN phosphatase activity were studied by using pNPP as a substrate. 
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Ni2+ was found to be the strongest stimulator while Zn2+ was found to be the inhibitor of CaN 
phosphatase activity (Figure 12).   
5.4 Construction of deletion mutants of CaN A 
Five deletion mutants of CaN A were constructed, expressed and purified as described 
in “Materils and Methods”. Two mutants were constructed by progressively deleting the 
regions at NH2-terminus of CaN A. Since the active site lies close to NH2-terminus, the 
region(s) essential for its phosphatase activity can be defined (Figure 13). Three mutants were 
constructed by progressively deleting the regions at C-terminus. The domains which have 
regulatory effects on its phosphatase activity can be defined since the auto-inhibitory, CaM-
binding and CaN B-binding domains are located close to C-terminus (Figure 13). The 
purified mutants were subjected to SDS-PAGE to confirm the purity and estimate their sizes 
(Figure 14). All the mutants were judged to be purified close to homogeneity. CaN A97-511 
(∆1), 49 kDa; CaN A201-511 (∆2), 37 kDa; CaN A1-456 (∆3), 52 kDa; CaN A1-406 (∆4), 48 
kDa; and CaN A1-358 (∆5), 42 kDa. 
5.5 CaN phophatase activity of WT and deletion mutants 
Once both the WT CaN A and the mutants were purified, they were tested for 
phosphatase activity assay to observe any changes due to deletion (Figure 15). WT CaN A 
alone showed some basal phosphatase activity increased almost 50% upon association with 
CaN B. However, the addition of EGTA caused inactivation of phosphatase activity in the 
presence of CaM.  This indicates that both CaN B and CaM are essential to achieve the full 
activity of CaN A. CaN A97-511 (∆1) did not display any significant difference in terms of  
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 basal phosphatase activity as well as CaN B- and CaM-dependence of phosphatase activity. 
This suggests that the deleted residues 1-97 at NH2-terminus do not have any impact on CaN 
A activity. However, CaN A201-511 (∆2) displayed reduced both basal and full activity 
compared to WT. This suggests that the amino acid residues 97-200 are important for CaN 
phosphatase activity.   
Moreover, CaN A 1-456 (∆3) displayed significant increase in both basal and full 
activity compared to WT. The truncated CaN A alone showed a ~30% increase compared to 
WT CaN A alone activity. When CaM is inactivated, CaN A1-456 still showed an equivalent 
phosphatase activity level compared to the full activity of WT CaN A, which needs to be 
activated by CaM (Figure 15). This must be due to the removal of autoinhibitory domain.  
Hence, binding of CaM is not required for CaN A1-456 (∆3) to free the active site from 
inhibition by autoinhibitory domain. Also, previous studies have demonstrated the reduction 
of inhibitory effect upon one amino acid mutation at position 477 Asp to Asn in the 
autoinhibitory domain (199). Thus, increase of catalytic activity can be achieved by removing 
or disruption of autoinhibitory domain.   
Furthermore, its phosphatase activity was further enhanced by nearly 40% when CaN 
A1-456 (∆3) was bounded to CaM (Figure 15). This confirms that CaM is essential for the 
maximum activity of CaN. It also suggests the autoinhibitory domain is not the only region 
responsible for the inhibition of phosphatase activity. When CaM is not binding to CaN A, 
there might be some type of structural obstruction prevent the substrate from accessing the 
catalytic site. This blockage can be removed upon binding of CaM to CaN A. 
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It is highly possible that when CaM is not binding to CaN A, the catalytic site is 
inhibited by some structural constraint. Upon binding of CaM, some conformational change 
might have occurred in the catalytic site. In this way, the catalytic site might have become 
more efficient to dephosphorylate its substrate. This observation agreed with the previous 
study on the synergism between the CaM-binding domain and autoinhibitory domain on CaN 
phosphatase activity (200).   
A further increase in both basal and full activity was observed from CaN A1-406 (∆4) 
(Figure 15). It implies that more inhibition was removed from the phosphatase activity. The 
residues at 406-456 contain inhibitory effect on the active site. This observation agrees with 
an earlier study by Perrino (201). A second autoinhibitory domain lies within residues 420-
457, which is located at the C-terminal to the CaM-binding domain (201). The second 
inhibitory effect could be removed when CaM binds to CaN A (201). This was also observed 
by inactivating CaM in the dephosphorylation by CaN A1-456 (∆3) (Figure 15). However, 
the presence of EGTA (the inactivation of CaM) did not have any impact on CaN A1-406 
(∆4) activity (Figure 15). This suggests that CaM-dependence of its activity was removed 
along with the deleted portion from C-termus. It also confirmed that the CaM-binding domain 
precedes the autoinhibitory domain in CaN A (201, 202). In contrast, it is not the case in other 
CaM-dependent proteins such as CaMPKs and myosin light chian kinase, wherein the CaM-
binding domain lies next to or partially overlaps with the autoinhibitory domain in the 
primary sequence (203-205).   
Moreover, CaN A1-358 (∆5) did not have any change in its maximum activity 
compared to WT CaN A (Figure 15). However, its basal activity was equivalent to its full 
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activity level. In other words, the CaN B-dependence of CaN A phosphatase activity was 
aborted due to the partially removal or disruption of CaN B-binding domain. In a similar way, 
inactivation of CaM did not change its activity either because of the removal of CaM-binding 
domain. Thus, CaN A1-358 (∆5) was independent of CaN B and CaM (Figure 15). 
Essentially, CaN A1-358 (∆5) was a Ca2+-independent form of CaN. It could be constitutively 
active because it is unable to sense any Ca2+ concentration change. Furthermore, CaN A1-358 
(∆5) demonstrated the importance of CaN B for CaN A to reach maximal activity. Even when 
the autoinhibitory domains were removed, CaN A phosphatase activity was at basal level 
(Figure 15). Similar finding was demonstrated in a previous study (206). Binding of CaN B is 
required for maximum CaN A activity.  
According to the current literature, the CaN A catalytic site is essentially formed by a 
β-sandwich with a loop, Loop 7, between two β-sheets (207). Loop 7 is very important for 
enzymatic activity and regulation of CaN (208). It forms close contact with the two 
immunophilin-immunosupressant complexes and the autoinhibitory domain (47, 209, 210).  
Deletion of individual residues in and around Val314 in Loop 7 resulted in reduced sensitivity 
to CsA but increased sensitivity to FK506; while the inhibition by autoinhibitory domain was 
removed (208). Moreover, when Asp313, Val314, Tyr315, Asn316 or Lys318 was 
individually deleted, CaN activity was dramatically increased (211, 212). In contrast, CaN 
activity was greatly reduced when Leu312 or Asn317 was deleted (211, 212). The CaN B- 
and CaM-dependence of CaN activity were also removed when Val314 or Tyr315 was deleted 
(211, 212). 
In addition, it has been demonstrated that mutations (Thr352, Leu354, Lys360) in the 
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CaN B-binding domain result in various extents of resistance to inhibition by CsA and FK506 
(213-215). Substitutions of residues 118-125 in CaN B also confer some extent of resistance 
to the inhibition (213-215). 
5.6 Dephosphorylation of 32P-labeled histone 
In order to further substantiate the phosphatase activity of WT CaN A and its mutants, 
we examined dephosphorylation of [γ-32P]-labelled histone by WT CaN and its mutants since 
pNPP is not a specific substrate for CaN phosphatase activity. Prior to performing the 
dephosphorylation of [γ-32P]-histone, histone was phosphorylated by using cAMP-PK in the 
presence of [γ-32P]ATP as described in “Materials and Methods”. [γ-32P]-labeled histone 
alone was used as the control representing 100% phosphorylation (Figure 16).   
All the experimental groups including WT CaN A and the five mutants were compared 
to the control. The amount of phosphorylation left in the reaction mixture of each group was 
calculated as percentages. Two groups of experiments were run separately in the 
presence/absence of CaM (Figure 16). In the presence of CaM, WT CaN A displayed more 
than 50% of dephosphorylation activity.  CaN A97-511 (∆1) dephosphorylated nearly 70% of 
phsophorylated histone. A similar dephosphorylation ability compared to WT CaN A was 
observed for CaN A201-511 (∆2). However, the remaining three mutants were demonstrated 
to have stronger dephosphorylation abilities. CaN A1-456 (∆3) and CaN A1-406 (∆4) 
removed 90% of phosphate group. CaN A1-358 (∆5) removed 75% of phosphate group.   
In contrast, when CaM is absent, WT CaN A only dephosphorylated 20% of 
phosphorylated histone (Figure 16). When there is no CaM, the autoinhibitory domain at the 
C-terminal region will bind to the active site to inhibit the CaN A phoshatase activity. 
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Figure 16 
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 CaM is needed to bind to CaN A and cause conformational change so that the 
autoinhibitory domain is positioned away from the active site. Thereby, CaN A 
phosphatase activity was reduced more than 50% in the absence of CaM. CaN A97-
511 (∆1) and CaN A201-511 (∆2) displayed similar dephosphorylation abilities 
compared to the WT CaN A. This was expected since both mutants were constructed 
by progressively deleting the N-terminal region while the autoinhibitory domain is 
located at C-terminal region. The other three mutants showed slightly reduced 
dephosphorylation activity in the absence of CaM; although the percentages of 
phosphate group being removed were still greater than that of WT CaN A (Figure 16). 
The presence or absence of CaM did not have very much influence on these mutants’ 
phosphatase activity. It is highly possible that the autoinhibitory domain of these three 
mutants has been removed or disrupted. In addition, the phosphatase activities of CaN 
A1-358 (∆5) in the presence/absence of CaM were very close. It indicates that CaN 
A1-358 (∆5) is CaM-independent. 
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5.7 Discussion 
Ca2+ acts as a second messenger in a number of different signaling pathways 
and plays a critical role in a myriad of different physiological and pathological 
processes (216, 217). Increase in intracellular Ca2+ concentration by stimulating the 
entry of extracellular Ca2+ or by release of Ca2+ ions from intracellular stores leads to 
the binding of Ca2+ to CaM, which then converts CaM to an active conformation. This 
active CaM involves a Ca2+-dependent reversible association of CaM with target 
protein(s) resulting in a change in target protein activity (218, 219). CaM-dependent 
enzymes participate in various physiological processes either directly, or indirectly, 
through the regulation of the activity of other cellular proteins by phosphorylation or 
dephosphorylation (220). These enzymes are involved in cell proliferation and 
differentiation by participating in Ca2+-dependent induction of gene transcription 
(221). 
The response of retinal photoreceptor cells to light is a second potential 
pathway for regulation by CaN. During the photoreceptor cycle a series of reactions 
result in a net decrease of cGMP concentrations in photoreceptors, causing an 
inactivation of cGMP-gated cation channels that allows the photoreceptor to extrude 
ions and the return to a resting potential (185). One of the ions regulated in this 
process is Ca2+. Intracellular Ca2+ concentrations in photoreceptors are also mediated 
by release from intracellular stores by the interaction of IP3 (186, 187, 222) with its 
receptor. CaN has been shown to regulate IP3 receptors in other tissues by 
dephosphorylation (80) and leads us to hypothesize that Ca2+ concentrations in 
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photoreceptors could also be regulated by CaN. These pathways involving CaN could 
suppress the amplitude of Ca2+ oscillations in photoreceptors facilitating a more rapid 
transition from the light- to the dark-adapted photoreceptor. Such a possible pathway 
could account for the relatively high amounts of CaN demonstrated in the retina. CaN 
is also involved in neuronal signal transmission and in the production and 
maintenance of myelin sheaths (223, 224). The relatively low levels of CaN in eye 
may make it particularly susceptible to the side effects of the CaN inhibitors Cs A and 
FK506.  
In order to study retina CaN, we have cloned and characterized the bovine 
retina CaN A and B subunits. Our present study revealed that when compared to 
bovine brain CaN A, retina CaN A is missing 10 amino acid residues (A-T-V-E-A-I-
E-A-D-E). We also observed that the retina CaN A is similar to cardiac CaN A (198). 
We assessed the role of the different domains of the CaN A subunit in the regulation 
of CaN activity using WT and various truncation mutants by measuring the 
Ca2+/CaM–dependent phosphatase activity towards a pNPP substrate. This deletion 
analysis confirmed that removal of the autoinhibitory domain (residues 457-511) of 
CaN A resulted in increased CaN A activity. Of particular interest, we find that 
deletion of the residues N-terminal to the autoinhibitory domain (residues 407-456) 
also significantly increased CaN A activity. This suggests that CaN A may contain 
two autoinhibitory domains or that the previously defined autoinhibitory domain 
extends further towards N-terminal to what had previously been reported (108). 
A dinuclear metal center has been proposed to be located in the catalytic site 
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of CaN A (225, 226). Several studies have identified a “phosphoesterase motif” that is 
conserved in PP1, PP2A, CaN and many other enzymes involved in the cleavage of 
phosphoester bonds (227-229). There are several ways that the metal ions of the 
dinuclear center could function to catalyze the phosphate ester hydrolysis. For 
instance, the Lewis acidity of the metal ions might act to activate a solvent molecule, 
such as water, to increase the nucleophilicity of the solvent (230). In addition, metal 
coordination of the phosphate ester might have positive effects to accelerate 
hydrolysis (207). For example, the electrophilicity of the leaving group could be 
increased by neutralizing the negative charge on the oxygen atoms of the phosphate 
ester (207). The metal ions could also help to stabilize the charge formation on the 
leaving group (207). 
In addition to the endogenous dinuclear metal ions, CaN activity is also 
regulated by exogenous divalent metal ions (66). Generally, these metal ions are 
classified into five categories based on their effects on CaN activity (66). First, the 
transition metal ions include Ni2+, Mn2+ and Co2+ are the strongest stimulators of CaN 
activity (192, 231-236). Mg2+ falls into a category of its own because of several 
unique features of its activation (234, 235). The third category includes Ca2+, Ba2+ and 
Sr2+, which are relatively less effective in activating CaN (232, 234, 235). The fourth 
category includes Be2+, Cu2+ and Fe2+, which do not stimulate CaN activity (192, 
231). The fifth category includes Zn2+ and Cd2+, which inhibit CaN activity (37, 237). 
Interestingly, bovine retina CaN was found to have a different feature from the 
previously reported.  Fe2+ was found to stimulate retinal CaN activity significantly. It 
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is highly possible that the interaction between Fe2+ and bovine retina CaN is different 
from the interaction between Fe2+ and CaN of other sources. However, the exact 
reason of such stimulation effect is yet to be explored. 
In addition, it has been proposed that metal ion stimulators might regulate the 
stubstrate specificity of CaN (66). For example, when myelin basic protein is used as 
substrate, CaN is stimulated by Mn2+ but inhibited by Ni2+ or Co2+ (233). 
Dephosphorylation of histone H1 and phosphorylase α by CaN were stimulated by 
Ni2+ to different extents (231). CaN activity were stimulated eight- and five-fold, 
respectively. This suggests that the stimulation effect is also dependent on the nature 
of phosphrylation site in substrate (66).   
Role of Ca2+ in CaN activity is closely related to the two protein regulators: 
CaN B and CaM, of CaN A. Many reports have revealed that Ca2+ exerts little or no 
stimulation on CaN activity in the absence of CaM (66). Ca2+ can not substitute for 
transition metal ions or Mg2+ to fulfill the metal ion requirement of CaN activity 
(237). Ca2+ is required for activation of CaM as well as the association of CaM and 
CaN B with CaN A. Both CaM and CaN B have four Ca2+ binding sites. Although 
CaN B and CaM share sequence homology, they are not replaceable for each other in 
order to activate CaN A. Both CaM and CaN B are required to fully activate CaN A 
phosphatase activity.  
The interaction between CaN and metal ions occurs at multiple levels. Firstly, 
CaN B is a Ca2+-binding protein. It enables the association of CaN A and CaN B upon 
binding of Ca2+ to CaN B (23). Secondly, Ca2+ is required for CaM to further activate 
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CaN A phosphatase activity (24). Thirdly, several divalent metal ions activate the 
enzyme to different extent (67, 236). Therefore, CaN contain endogenous metal ions; 
also, it interacts with exogenous metal ions and CaM in a metal ion-dependent 
interaction. 
 Calpains are Ca2+-activated cysteine proteases which are major mediators for 
Ca2+ signals in many biological systems including the altering the function of kinases 
and phosphatases (238, 239). There are at least two types of calpains, µ- and m-
calpains, which require micromolar and millimolar concentrations of Ca2+ for 
activation, respectively (238). Ca2+-dependent cysteine proteases, such as calpain 
have suggested to cleave polypeptide sequences enriched in proline (P), glutamic acid 
(E), serine (S) and threonine (T), known as PEST motifs (240). Calpastatin, an 
endogenous protein inhibitor regulates the activity of calpains (241). Deregulation of 
the calpain-calpastatin system has been implicated in various neurodegenerative 
disorders (242, 243). PEST sequences are believed to be the intramolecular signals for 
rapid proteolytic degradation by m-calpains. It has been suggested that PEST regions 
may not be responsible for the calpain-mediated proteolysis (244).  
It has been reported that bovine brain 60 kDa CaMPDE has a single strong 
PEST motif (amino acid residues 73-94), and a PEST score 7.36 (245). It has been 
reported that PDE1A2 isozyme is proteolysed by calpain into a 45 kDa catalytic 
fragment and a 15 kDa fragment. The cleavage occurs between residues 126Gln and 
127Ala (246). This eliminates the CaM-dependent activity of carboxy termini of 60 
kDa CaMPDE isozyme, resulting in its conversion to a totally CaM-independent form 
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(246).  
The domain organization of CaN A is shown in figure 3. CaN A contains 
catalytic (residues 70-333) and regulatory (residues 390-521) domains. The regulatory 
domain contains a CaN B binding helix, a CaM-binding domain and an autoinhibitory 
domain. The regulatory domain is readily susceptible to proteolysis in the absence of 
CaM (247). We reported that the m-calpain-mediated proteolysis of CaN A resulted in 
the induction of CaN phosphatase activity (108) and CaN A became completely CaM-
independent. Wang et al. (248) reported that, upon proteolysis of CaN by µ-calpain, 
the phosphatase activity measured in the presence of CaM increased by 300%. In 
addition, CaN activity increased by 50% in response to m-calpain proteolysis 
(measured in the presence of CaM). Tallant et al. (249) reported that CaN was 
converted to an active CaM-independent form by µ-calpain-mediated proteolysis. 
Trypsin proteolysis of CaN in the absence of CaM resulted in the degradation of the 
60 kDa subunit to a 43-45 kDa fragments that became CaM-independent after 
proteolysis (250). 
 We observed CaN A was proteolysed to a 46 kDa fragment in the presence of 
Ca2+ and 48 and 54 kDa in the presence Ca2+/CaM (108). All three of these 
proteolytic products possessed phosphatase activity, suggesting that each contains the 
N-terminal catalytic domain of CaN A. The CaM overlay experiment showed that the 
CaM-binding domain was present in the 54 kDa proteolytic fragment suggesting the 
m-calpain cleavage occurs after the CaM-binding domain of CaN A. However, 46 and 
48 kDa fragments lacked the CaM-binding domain, suggesting they were cleaved N-
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terminal to the CaM-binding domain. However, further studies are warranted to 
identify precise cleavage site(s) by m-calpain on CaN A.  
A series of truncated mutants were constructed, expressed and purified as 
described in Materials and Methods. Figure 13 shows a schematic representation of 
various deletion mutants for CaN A. Two different mutants were prepared by deleting 
progressively larger N-terminal regions of catalytic domain of CaN A to define which 
region(s) of this domain were essential for CaN phosphatase activity. 1 CaN A97-
511 and 2 CaN A201-511 mutants were constructed by deleting the indicated 
number of amino acid residues. No significant change in phosphatase activity was 
observed for mutants 1 CaN A97-511 compared to WT CaN A, while 2 CaN 
A201-511 showed 20% decrease in CaM-dependent phosphatase activity (Figure 15). 
To further substantiate the CaN phosphatase activity measured using pNPP as a 
substrate, the dephosphorylation of [γ-32P]-labeled histone as a substrate was carried 
out. We observed a similar pattern of dephosphorylation of histone using WT CaN 
and various truncated mutants (Figure 16). These results indicated that the deletion of 
the first 97 amino acids of CaN A had no impact on the phosphatase activity of retinal 
CaN.  
Three C-terminally truncated mutants were constructed to assess the role of 
different regions with the regulatory domain of CaN A in the regulation of CaN A 
phosphatase activity. Furthermore, the truncated mutant 3 CaN A1-456 was prepared 
by deleting ten additional residues within the autoinhibitory domain of CaN A. The 
retinal CaN phosphatase activity was increased to 31% in the mutant 3 CaN A1-456. 
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Moreover, we observed CaM was essential for the maximum activation of 3 CaN 
A1-456 mutant, demonstrating that the autoinhibitory domain alone is not responsible 
for the inhibition of phosphatase activity of CaN. These results are in agreement with 
the report of Tokoyoda et al (200) and Lakshmikuttyamma et al (108). Furthermore, 
we have generated a further truncated CaN A mutant ( 4 CaN A1-406), to evaluate 
which part of the CaM-binding domain was responsible for CaM binding. This further 
deletion results in further phosphatase activation. For this particular mutant no 
significant change was observed in CaM-independent and dependent phosphatase 
activity of CaN, and it showed a 46% higher activity compared to WT CaN. This 
result revealed that all amino acid residues (391-414) in the CaM-binding domain are 
not involved in the regulation of phosphatase activity. From these data it appears that 
N-terminal sequences of CaM-binding domain (407-414) are responsible for the 
inhibition of phosphatase activity of retinal CaN. The truncated mutant 5 CaN A1-
358 was made by deletion of amino acid residues EKVTEMLVDV of the CaN B 
binding domain. Compared to WT CaN A, no change in phosphatase activity was 
observed for 5 CaN A1-358 by the addition of CaN B. Previous reports 
demonstrated that the peptide corresponding to the residues 348-367 in brain CaN A 
was able to inhibit the phosphatase activity and indicate the participation of these 
residue in the binding of CaN B to the catalytic subunit [251]. 
Deletion of the autoinhibitory domain and CaM-binding domain has been 
shown to be essential for the induction of CaN activation (200). The analysis also 
indicated that the deletion of only one domain was insufficient for the activation of 
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CaN. The synergy between these two domains is crucial for the Ca2+ dependent 
regulation of phosphatase activity of CaN (200). The removal of these two domains 
during calpain-mediated proteolysis may be the reason for the enhanced activity of 
proteolysed CaN. With most CaM regulated enzymes, the mechanism of CaM 
activation is believed to involve binding to the CaM-binding domain, and consequent 
displacement of an auto inhibitory domain. This model was supported by crystal 
structure analysis of the native CaN molecule showing that the structure of the CaM-
binding domain to the COOH terminal end was not visible (47, 209). Thus it is likely 
that the COOH terminal end from the CaM-binding domain may be structurally 
unstable.  
 In recent years, it has been increasingly recognized that Ca2+/CaM–
dependent protein phosphatase CaN provides a critical link between Ca2+ regulation, 
synaptic plasticity, and cell survival (251). Over-expression of CaN in young adult 
animals leads to altered synaptic function and memory retention deficits (252). In 
hippocampal neurons, activation of CaN results in the inhibition of the release of 
neurotransmitters, glutamate and γ-aminobutyric acid (253), as well as desensitization 
of post synaptic NMDA receptor-coupled Ca2+ channels (254). Excess stimulation of 
CaN, by raising intracellular Ca2+ levels, releases CaN into the cytosol. In the cytosol, 
it may cause neuronal apoptosis via dephosphorylation of key cytosolic components, 
such as the Bcl family member Bcl-2 associated death protein (BAD) and cAMP 
response element binding protein (CREB) (253). The altered regulation of CaN is one 
of the processes that could link Ca2+ dyshomeostasis to age related changes in 
 66
neuronal function and cognition (255). CaN inhibitors FK 506 and Cs A are used for 
differential neuroprotection following ischemia and treatment of ameliorated 
glutamate toxicity and delayed neuronal death (255-257). Recent studies suggest that 
a significant increase in both basal and maximal activity of CaN were observed in 
epileptic rats (258). These results support the hypothesis that CaN is toxic for neurons 
and may contribute to various neurological disorders. The activation of CaN by 
calpain mediated proteolysis could be a regulating mechanism for the over-expression 
of this enzyme in brain neurons. Alterations in intracellular Ca2+ homeostasis and the 
activation of calpains have been implicated in various neurodegenerative disorders 
like Alzheimer’s disease, ischemia and epilepsy (242, 259-261).  
The major signaling pathway of CaN in the development of malignancy may 
be through NFAT. In T cells, CaN-NFAT signaling represents a critical event for 
mediating cellular activation and the immune response (262, 263). Cell-mediated 
immune responses are an essential aspect of tumor-host interactions in colorectal 
cancers. The progression from precancerous (adenomatous) colon polyps to malignant 
colorectal cancer depends on a complex pathway involving the activities of activated 
T lymphocytes (264). The important role of CaN in T-cell activation is underscored by 
the effects of immunosuppressive drugs, such as CsA and FK506, which inhibit CaN 
activity (265). The activation of T cell receptors recruit a large array of necessary 
intracellular signaling mediators such as mitogen-activated protein kinase family 
members, tyrosine kinases (Fyn-T, Lck, Syk, and Zap70) NF-kB, Jak/Stat, PKCθ and 
various cytokines (266-270). The elevated levels of IL-8 gene expression in human 
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colonic epithelial cells occur through the activation of nuclear factor-kappa B (NF-
kB) (271) and are regulated by CaM-dependent CaN (272). Elevated levels of 
circulating plasma cytokines IL-6 and IL-8 have been reported in cancer patients 
(273). RelA/NF-kB, an important inhibitor of apoptosis is significantly increased in 
the transition from adenoma with low dysplasia to adenocarcinoma in colorectal 
tumorigenesis (274). It has been reported that CaN may regulate integrin-dependent 
cell adhesion and spread of Colo201 cells (275). Furthermore, CaN may also be 
involved in the regulation and establishment of new adhesive interactions in HT29, a 
colon cancer cell line (276).  
The involvement of CaN with various apoptotic factors and whether this 
Ca2+/CaM-dependent phosphatase has any role in inhibiting apoptosis is unclear. 
Simizu et al. reported that Bcl-2 inhibits CaN-mediated Fas ligand expression in anti-
tumor drug-treated baby hamster kidney cells (277). Recently Ca2+-dependent 
interaction of CaN with Bcl-2 was reported in neuronal tissues (278). CaN bound to 
Bcl-2 is an active phosphatase but is unable to promote the nuclear translocation of 
NFAT, a transcription-factor required for induction of interleukin-2 expression, 
suggesting a mechanism by which Bcl-2 suppresses NFAT activity. Direct interaction 
between Bcl-2 and CaN has been reported in BHK-21 cells transfected with both 
proteins (279). Dephosphorylation of Ser70 of Bcl-2 by CaN is required for 
antiapoptotic effects of Bcl-2. The overexpressed CaN in human colorectal 
adenocarcinoma may provide protection against apoptosis by dephosphorylating Bcl-
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2 (280). In apoptosis, proteolysis is very important in altering or disabling the 
function of many enzymes involved in signal transduction.  
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6.0 CONCLUSION 
Both CaN A and CaN B recombinant proteins were successfully cloned and 
purified from bovine retina in this study. The DNA sequence of CaN A was obtained 
and deduced to amino acid sequence. The peptide sequence of bovine retina CaN A 
was 10 amino acids shorter than that of bovine brain CaN A (Figure 8). There was one 
amino acid substitution at 367.  Highly conserved CaN A sequence in mammalian 
tissues implies important physiological roles of CaN. Reconstitution assay was carried 
out to confirm that CaN phosphatase activity achieves maximal level at 1:2 molar 
ratio of CaN A/CaN B (Figure 11). It was also found that Ni2+ is the strongest 
stimulator of CaN phosphatase activity while Zn2+ inhibits the activity (Figure 12). 
However, Fe2+ also stimulated CaN phosphatase activity. Deletion analysis was 
carried out to study the domain organizations of CaN A. It indicates that the amino 
acid residues 97-201 are essential to the phosphatase activity because CaN A201-511 
showed reduced activity level (Figure 14). It appears that there might be another 
inhibitory site presents between amino acid residues 457-414 because CaN A1-406 
showed increased activity level compared to CaN A1-456. As a result, CaN A from 
bovine retina possesses some distinct structural features compared to bovine brain 
CaN A. The unique structural features might result in some different catalytic and 
regulatory characteristics.   
In order to further study this protein, the three-demensional structure of bovine 
retina CaN A needs to be resolved. The understanding of unique structural and 
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biochemical characteristics of bovine retina CaN A would provide clues to investigate 
the physiological roles of such protein in eye. The response of retinal photoreceptor 
cells to light might be a potential pathway for CaN to be involved. During 
photoreceptor cycle, a series of biochemical reactions including inactivation of 
rhodopsin through phosphorylation and decrease of cGMP concentration through 
action of PDE will take place. CaN phosphatase activity could act on both events to 
bring photoreceptor cells to a state ready for next cycle of response to light. Such a 
possible pathway could account for the relatively high level of CaN phosphatase 
activity in retina (180). The present study demonstrates the first investigation on the 
structural and biochemical characteristics of CaN from bovine retina. It also provides 
some fundamental knowledge of retina CaN for further studies on eye diseases. 
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